ReproCyc PRRS-PLE (Canada)This page contains information on ReproCyc PRRS-PLE for veterinary use.
The information provided typically includes the following:
- ReproCyc PRRS-PLE Indications
- Warnings and cautions for ReproCyc PRRS-PLE
- Direction and dosage information for ReproCyc PRRS-PLE
ReproCyc PRRS-PLEThis treatment applies to the following species:
Porcine Reproductive and Respiratory Syndrome-Parvovirus Vaccine, Reproductive Form, Modified Live and Killed Virus-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin
Veterinary Use Only
Read entire insert before use.
ReproCyc PRRS-PLE Indications
Recommended for the vaccination of healthy, susceptible sows and gilts, as an aid in the reduction of disease associated with porcine reproductive and respiratory syndrome virus, reproductive form, and as an aid in the prevention and control of disease caused by porcine parvovirus, Erysipelothrix rhusiopathiae and Leptospira canicola-grippotyphosa-hardjo-icterohaemorrhagiae-pomona. For use only in healthy susceptible animals in “PRRS virus positive herds” per label direction. PRRS positive herds means any herds that are PRRS serological positive, PRRS isolation positive or PRRS clinical symptom positive. Many factors must be considered in determining a sound PRRS vaccination program for a particular farm. To be most effective, the vaccine must be administered properly to healthy animals maintained in a proper environment under good management. Stressed or immunosuppressed pigs should not be vaccinated as the efficacy of the vaccine in these animals is unknown. Seldom does one vaccination under field condition produce lifetime protection for all individuals in a given herd. The level of individual animal and herd immunity required will vary with management practices, the degree of exposure to PRRS virus, and the level of susceptibility of each animal. The benefits and risks from vaccination will vary in part with the level of PRRS virus in the herd. The PRRS status of the herd or individual animals should be assessed by virus isolation, serological, or other diagnostic tests. Therefore, the vaccination program must be carefully planned and implemented following label and insert indications and precautions and the direction of a veterinarian.
Directions For Use
Rehydrate the vaccine by adding the accompanying bacterin diluent to the vaccine vial. Shake well and use immediately. Rehydrate only with the bacterin diluent provided; do not use with other materials. Other diluents may be virucidal.
Dosage: Using aseptic technique, administer a single 5 mL dose intramuscularly to gilts and sows 4-6 weeks prior to breeding. The duration of immunity is at least 4 months or throughout gestation. Revaccinate with Parvovirus Vaccine-Erysipelothrix Rhusiopathiae-Leptospira Canicola-Grippotyphosa-Hardjo-Icterohaemorrhagiae-Pomona Bacterin, Killed Virus, in 3 to 4 weeks. Revaccinate with a single dose prior to each subsequent breeding. Administer only to healthy gilts and sows in PRRS virus positive herds, and only by intramuscular injection. Administer the complete 5 mL dose to each gilt and sow vaccinated. Efficacy and safety of the vaccine at other than the dose or route prescribed on the label is unknown, and therefore not recommended.
PrecautionsFor use only in swine in PRRS virus positive herds as directed by a veterinarian. Vaccine virus may be shed and transmitted to other populations of swine which are in contact with vaccinated swine. The duration of potential vaccine virus transmission may vary by animal. Vaccine virus may be found at varying times post vaccination at locations (tonsil, nasal mucosa, urine, feces) from which the potential for shedding exists. Shedding of vaccine virus may be increased by glucocorticoid treatment and possibly by disease or environmental conditions which stress pigs and elevate levels of endogenous glucocorticoids. Use of the vaccine on farms or pigs transported from the farms where vaccine has been used to farms wanting to remain PRRS virus seronegative is contraindicated. The effect of concurrent or previous infections at or around the time of vaccination on the efficacy of this vaccine in reducing or modifying PRRS virus disease in pigs is not known.
Do not vaccinate pregnant sows or gilts, or boars of breeding age. Vaccination during the latter part of gestation of pregnant sows or gilts which are PRRS virus naive and previously unvaccinated can result in piglets born vaccine viremic. The impact of vaccine viremia in the newborn pig is not known.
Vaccination of PRRS negative herds prior to breeding may result in a transient reduction of reproductive performance.
Vaccination of adult boars may result in the shedding of vaccine virus in the semen. Because the impact of shedding is not known, do not use in boars of breeding age.
Do not vaccinate within 21 days before slaughter.
StorageStore in dark at 2-7°C. Use entire contents when first opened. Burn containers and all unused contents.
Anaphylactoid reactions may occur.
Preservatives: Amphotericin B, gentamicin, neomycin, and thimerosal.
Manufactured by: Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO 64506 USA
US Veterinary License No. 124
Manufactured for: Boehringer Ingelheim (Canada) Ltd., Burlington, Ontario L7L 5H4
20 doses (100 mL)
5180 SOUTH SERVICE ROAD, BURLINGTON, ON, L7L 5H4
|Customer Care No.:||800-567-1885|
|Technical Services No.:||1-877-565-5501|
|Every effort has been made to ensure the accuracy of the ReproCyc PRRS-PLE information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.|
Copyright © 2017 North American Compendiums. Updated: 2017-10-31